Rinvoq is the brand name for upadacitinib, a JAK1-selective Janus kinase inhibitor manufactured by AbbVie. The FDA first approved Rinvoq in August 2019 for moderate to severe rheumatoid arthritis, then expanded approval to psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, moderate to severe atopic dermatitis, ulcerative colitis, Crohn's disease, and giant cell arteritis. Rinvoq is a once-daily extended-release tablet taken orally, unlike biologic competitors such as Humira and Skyrizi that require injection. The FDA requires a boxed warning on Rinvoq covering increased risk of serious heart-related events, cancer, blood clots, and death, based on safety data from a related JAK inhibitor trial, so prescribers weigh this risk profile before prescribing, particularly in patients age 50 or older with existing cardiovascular risk factors. Rheumatologists, dermatologists, and gastroenterologists prescribe Rinvoq after patients have tried and failed lower-cost conventional therapies, which is one reason payers scrutinize prior authorization requests so closely before approving a fill.
AbbVie's wholesale acquisition cost for Rinvoq reached approximately $7,090.41 per 30-day supply as of January 2026, regardless of whether a patient takes the 15 mg, 30 mg, or 45 mg extended-release tablet. Dosing and duration depend on the indication: rheumatoid arthritis and psoriatic arthritis typically use 15 mg once daily long-term, while ulcerative colitis and Crohn's disease often start with a higher 45 mg induction dose before stepping down to a 15 mg or 30 mg maintenance dose. Because the price is set per 30-day supply rather than per dose strength, what a patient actually owes depends heavily on insurance type, indication, and whether AbbVie's savings programs apply. Patients also managing other autoimmune biologics should compare Skyrizi's cost breakdown or Humira's biosimilar switch options, since most payers require documented failure of a TNF inhibitor like Humira before approving Rinvoq.
Rinvoq has become one of AbbVie's fastest-growing revenue drivers as Humira lost patent exclusivity and faced biosimilar competition starting in 2023. In September 2025, AbbVie settled patent litigation with generic manufacturers that had filed applications to sell generic upadacitinib, pushing expected generic entry out to approximately April 2037 in the United States. The Centers for Medicare & Medicaid Services has not selected Rinvoq for Inflation Reduction Act price negotiation in either the first round (effective 2026) or the second round of 15 drugs (effective 2027), so there is no government-negotiated Maximum Fair Price for this drug in 2026. Medicare patients relying on Rinvoq should review the Medicare Part D annual out-of-pocket cap rules that apply instead, since that $2,100 cap, not IRA negotiation, is what limits their annual spending on this drug. Future negotiation cycles could eventually add Rinvoq if Part D spending on the drug keeps climbing.
What Rinvoq Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same rinvoq can cost many times more at a hospital than at your local pharmacy:
2026 Rinvoq Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter (retail, cash) | $6,245 - $9,104/month | List price for a 30-day supply without insurance in 2026 |
| Medicare Part D (2026) | Formulary-tier copay, capped at $2,100/year total | Usually placed on the highest specialty tier; prior authorization required |
| Commercial insurance with Rinvoq Complete card | As low as $0/prescription (up to $14,000/year) | Not available with Medicare, Medicaid, TRICARE, or VA coverage |
| Medicaid | $1 - $4/prescription, with PA | Covered for FDA-approved indications; step therapy varies by state |
Retail figures reflect 2026 GoodRx and AbbVie wholesale acquisition cost data. Part D copays depend on your plan's formulary tier and where you are in the benefit year.
Source: CMS Part D 2026 benefit design, AbbVie Rinvoq Complete, GoodRx
Why Hospitals Charge So Much
Rinvoq is almost always self-administered at home as a once-daily oral tablet, so it rarely generates a hospital bill on its own. When Rinvoq does appear on an inpatient itemized bill, it is usually because a patient continued their home medication during a hospital stay for an unrelated condition, such as a surgery, a Crohn's disease flare requiring admission, or an infection, and the hospital pharmacy dispensed the tablets from its own stock rather than the patient's home supply. Hospital pharmacies routinely mark up outpatient-style oral medications with facility fees, pharmacy handling charges, and medication reconciliation fees that can push a 30-day-equivalent supply well above the retail cash price. Patients admitted for a flare of an autoimmune condition Rinvoq treats, like ulcerative colitis or Crohn's disease, should specifically ask whether the hospital billed the drug itself or only the nursing time associated with administering it.
AbbVie's 2026 wholesale acquisition cost of roughly $7,090 per 30-day supply is the benchmark to compare against any inpatient drug-line charge. Ask for an itemized bill and the National Drug Code (NDC) whenever Rinvoq appears on a hospital statement, and confirm the tablet strength billed (15 mg, 30 mg, or 45 mg) matches your actual prescription. Charges significantly above the wholesale acquisition cost, separate from any facility or nursing fees, are common dispute targets, and most commercial insurance and Medicare will only reimburse at the outpatient pharmacy benefit rate rather than the inflated inpatient drug-line rate. If your Part D plan denies the inpatient claim because Rinvoq should have been billed through your outpatient pharmacy benefit instead, request a corrected claim rather than paying the hospital's cash-price line item directly.
Patient Assistance Programs
AbbVie, the manufacturer of Rinvoq, runs two primary assistance tracks: a copay savings card for commercially-insured patients and a free-drug patient assistance program for uninsured and underinsured patients. If you have no insurance, the myAbbVie Assist patient assistance program is generally the largest cost reduction available, often bringing your total Rinvoq cost to $0.
Patient assistance programs for Rinvoq| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Rinvoq Complete Savings Card | As low as $0 per prescription for commercially-insured patients, up to $14,000 per calendar year | rinvoq.com/resources/save-on-rinvoq-costs |
| myAbbVie Assist Patient Assistance Program | Free Rinvoq for uninsured patients at or below 600% of the federal poverty level; also available to some Medicare Part D patients without Extra Help | abbvie.com/myabbvieassist |
| Patient Access Network (PAN) Foundation autoimmune disease funds | Copay and premium assistance grants for Medicare patients with rheumatoid arthritis, atopic dermatitis, or inflammatory bowel disease, subject to fund availability | panfoundation.org |
| NeedyMeds Drug Discount Card | Variable discount accepted at most US pharmacies, not specific to Rinvoq | needymeds.org |
Manufacturer copay cards and coupons like Rinvoq Complete are blocked by federal anti-kickback law (42 U.S.C. § 1320a-7b) for anyone with Medicare, Medicaid, TRICARE, or VA coverage. A manufacturer coupon lowers your copay but does not lower what your insurer is billed, which is why federal law treats it as a kickback risk when a government program pays the claim. If you have government insurance, apply for myAbbVie Assist or a PAN Foundation grant instead. Medicaid beneficiaries generally do not qualify for myAbbVie Assist because Medicaid already covers Rinvoq with a small state copay.
Source: AbbVie patient support pages, PAN Foundation, NeedyMeds.org
Medicare Part D
Rinvoq is a Medicare Part D drug. For 2026, your total annual out-of-pocket cost across all Part D drugs combined is capped at $2,100 under the Inflation Reduction Act. Most Part D plans place Rinvoq on their highest specialty tier, which typically means 25% to 33% coinsurance until you reach the annual cap, after which you pay $0 for the rest of the calendar year on covered drugs, including Rinvoq. Because Rinvoq's monthly retail price of roughly $7,090 to $9,104 far exceeds the $2,100 cap on its own, most Medicare patients on Rinvoq will hit their annual out-of-pocket maximum within the first one to two months of the plan year and pay nothing for the remainder of the year on this and every other covered Part D drug.
Prior authorization and step therapy are standard for Rinvoq under Medicare Part D and most commercial plans. Many formularies require documented failure of, or intolerance to, a lower-cost biologic such as adalimumab (Humira and its biosimilars) or a TNF inhibitor before approving a JAK inhibitor like Rinvoq, given its boxed warning for cardiovascular and cancer risk. Ask your prescriber's office to submit the prior authorization with full treatment history and safety documentation to avoid a delayed or denied first fill. Plans reviewing a Rinvoq request also frequently ask for age, smoking history, and existing cardiovascular risk factors, since the FDA boxed warning specifically flags additional risk for patients age 50 and older with at least one cardiovascular risk factor.
The Medicare Prescription Payment Plan, available since 2025, lets Part D enrollees spread their out-of-pocket Rinvoq costs evenly across the calendar year instead of paying a large coinsurance bill in the month of the first fill. Ask your Part D plan to enroll you if a single Rinvoq fill would otherwise create a large upfront bill. This payment plan does not lower the total $2,100 annual cap; it simply divides that amount into smaller monthly installments so a single specialty-tier prescription does not create a cash-flow crisis in January.
Common Rinvoq Billing Errors
If you received a Rinvoq bill above $2,100 for the year under Medicare Part D, or a commercial bill over $300 with the Rinvoq Complete card active, check for these issues before paying:
- Prior authorization not submitted, or step therapy documentation of a failed TNF inhibitor missing, causing a denial and a full cash-price bill.
- Wrong dose strength billed. The 15 mg, 30 mg, and 45 mg tablets carry the same 30-day list price, but a pharmacy error billing multiple strengths in one month can double your claim.
- Rinvoq Complete copay card not applied at the specialty pharmacy counter even though you have qualifying commercial insurance. Ask the pharmacy to rerun the claim with the savings card BIN/PCN before paying cash.
- Coinsurance charged at the full formulary-tier rate after you already crossed the $2,100 Part D out-of-pocket cap for the year.
- Copay accumulator or copay maximizer programs that prevent Rinvoq Complete savings from counting toward your deductible, leaving you owing the full deductible later in the year.
- Hospital pharmacy billing a facility fee and a separate drug-handling fee on top of the standard 30-day drug charge for continuing home medication during a hospital stay.
Frequently Asked Questions
Is there a generic for Rinvoq?
No. As of 2026, there is no FDA-approved generic version of Rinvoq (upadacitinib). In September 2025, AbbVie settled patent litigation with generic manufacturers, pushing expected generic entry out to approximately April 2037. Rinvoq is a small-molecule oral drug, so it will eventually get a true generic rather than a biosimilar. Patients looking for a lower-cost alternative in a related drug class can ask their prescriber about biosimilar adalimumab, a lower-cost version of Humira.
How do I apply for the AbbVie myAbbVie Assist patient assistance program for Rinvoq?
Visit abbvie.com/myabbvieassist or call 1-800-222-6885 to start the application. You and your prescriber both complete sections of the form, and you submit proof of income, proof of US residency, and proof of your insurance status. Uninsured patients earning up to 600% of the federal poverty level generally qualify for free Rinvoq. Processing typically takes 7 to 14 business days, and approved patients receive up to 12 months of medication before needing to reapply.
Can I use the Rinvoq Complete savings card with Medicare?
No. Federal anti-kickback law prohibits manufacturer copay savings cards, including Rinvoq Complete, from being used by anyone with Medicare, Medicaid, TRICARE, or VA coverage. Rinvoq Complete is reserved for commercially-insured patients and can lower your cost to $0 per prescription, up to $14,000 per year. If you have Medicare, apply for the myAbbVie Assist patient assistance program or a foundation grant instead.
What if my insurance denies coverage for Rinvoq?
First, request the written denial notice, which states the specific reason. File a formal internal appeal within your plan's deadline (typically 60 to 180 days) and ask your prescriber to submit clinical documentation showing prior TNF inhibitor failures or contraindications. If your plan requires step therapy through Humira first, your prescriber can request a step-therapy override. If the appeal still fails, apply for the myAbbVie Assist program while you pursue an external review.
Does the IRA negotiated price apply to Rinvoq?
No. Rinvoq was not selected for Medicare drug price negotiation under the Inflation Reduction Act in the first round (effective 2026) or the second round of 15 drugs (effective 2027). There is no negotiated Maximum Fair Price for Rinvoq as of 2026. Medicare Part D enrollees instead rely on the general $2,100 annual out-of-pocket cap that applies to all Part D drugs combined in 2026, regardless of negotiation status.
What does Rinvoq cost without insurance at the pharmacy counter in 2026?
The 2026 cash price for a 30-day supply of Rinvoq 15 mg ranges from about $6,245 to $9,104 depending on the specialty pharmacy, with AbbVie's wholesale acquisition cost near $7,090. Discount cards like GoodRx or SingleCare can bring the price closer to $6,568 at some pharmacies. Uninsured patients should apply for the myAbbVie Assist program before paying cash long-term.
Do I qualify for the myAbbVie Assist patient assistance program?
You likely qualify if you are uninsured, a US resident, have a valid Rinvoq prescription, and your household income is at or below 600% of the federal poverty level (for example, about $198,000 for a household of 4 in 2026). Some Medicare Part D patients without the Extra Help Low-Income Subsidy can also qualify, but they must first apply for or be denied Extra Help. Medicaid beneficiaries generally do not qualify because Medicaid already covers Rinvoq.
How does Rinvoq's cost compare to other JAK inhibitors like Xeljanz or Cibinqo?
Rinvoq, Xeljanz (tofacitinib), and Cibinqo (abrocitinib) are all oral JAK inhibitors with similar specialty-tier pricing, generally $6,000 to $9,500 per 30-day supply in cash before assistance. Rinvoq's 2026 wholesale list price of about $7,090 sits between Xeljanz's older, somewhat lower pricing and Cibinqo's comparable range. All three carry the same FDA boxed warning for cardiovascular events, cancer, blood clots, and death, and all three require prior authorization and documented TNF-inhibitor failure under most Part D and commercial formularies.
